Trials / Completed
CompletedNCT03924375
Serum Pepsinogen After H. Pylori Eradication
Serum Pepsinogen After Helicobacter Pylori Eradication for the Gastric Cancer Prevention
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Soonchunhyang University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention. Considering the "point of no return" theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.
Detailed description
This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication.
Conditions
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2020-03-15
- Completion
- 2020-05-31
- First posted
- 2019-04-23
- Last updated
- 2020-07-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03924375. Inclusion in this directory is not an endorsement.